Eusol Biotech

Executive Summary

Eusol Biotech, headquartered in Taipei, Taiwan, is a publicly traded biotechnology company founded in 2005 that specializes in developing recombinant human acidic fibroblast growth factor (rhFGF1) therapeutics for nerve injury and related indications. Its lead candidate, ES135 (rhFGF1), has advanced to Phase 3 clinical trials for spinal cord injury, representing a significant milestone in a high-unmet-need area. The compound is also being evaluated for peripheral nerve disorders, broadening its potential application. To complement its pipeline, Eusol engages in strategic partnerships to develop niche generics and co-manufacture specialty formulations, providing near-term revenue streams. With a focused R&D strategy and a balanced business model, the company is positioned to address critical neurological conditions while maintaining operational flexibility.

Upcoming Catalysts (preview)

• Q3 2027Phase 3 Top-Line Results for ES135 in Spinal Cord Injury55% success
• Q2 2027Initiation of Phase 2 Trial for ES135 in Peripheral Nerve Disorders70% success
• Q1 2028New Licensing or Partnership Agreement for ES135 Outside Asia40% success